Dipeptidyl peptidase-1 inhibitors may influence treatment outcomes in bronchiectasis, as explored in this analysis.
The study discusses treatment complexities, emphasizing the interdependence of various drugs in managing bronchiectasis.
Observational analysis of treatment impacts suggests that no drug operates in isolation, affecting bronchiectasis outcomes.
Understanding the role of dipeptidyl peptidase-1 inhibitors may inform future treatment strategies for bronchiectasis.
Abstract
"Positioning Dipeptidyl Peptidase-1 Inhibitors in Bronchiectasis: No Drug Is an Island." American Journal of Respiratory and Critical Care Medicine, 0(ja), pp.